BACKGROUND: Health risks associated with subclinical hypothyroidism in older adults are unclear. Our objective was to compare the functional mobility of people aged 70 to 79 years by thyroid function categorized by thyrotropin (TSH) level as euthyroid (>or=0.4 to <4.5 mIU/L), mild subclinical hypothyroid (>or=4.5 to <7.0 mIU/L), or moderate subclinical hypothyroid (>or=7.0 to <or=20.0 mIU/L with a normal free thyroxine level) cross-sectionally and over 2 years. METHODS: A total of 2290 community-dwelling residents participating in the year 2 clinic visit (July 1998-June 1999) of the Health, Aging, and Body Composition (Health ABC) Study, who had measured TSH level, had the capacity to walk 20 m unaided, and were not taking thyroid medication or had TSH levels consistent with hyperthyroidism or hypothyroidism. Main outcome measures included self-reported and performance-based measures of mobility (usual and rapid gait speed and endurance walking ability) assessed at study baseline (year 2) and 2 years later. RESULTS: In age- and sex-adjusted analyses, the mild subclinical hypothyroid group (vs the euthyroid group) demonstrated better mobility (faster mean usual and rapid gait speed [1.20 vs 1.15 m/s and 1.65 vs 1.56 m/s, respectively; P < .001] and had a higher percentage of those with good cardiorespiratory fitness and reported walking ease [39.2% vs 28.0% and 44.7% vs 36.5%, respectively; P < .001]). After 2 years, persons with mild subclinical hypothyroidism experienced a similar decline as the euthyroid group but maintained their mobility advantage. Persons with moderate subclinical hypothyroidism had similar mobility and mobility decline as the euthyroid group. CONCLUSION: Generally, well-functioning 70- to 79-year-old individuals with subclinical hypothyroidism do not demonstrate increased risk of mobility problems, and those with mild elevations in TSH level show a slight functional advantage.
BACKGROUND: Health risks associated with subclinical hypothyroidism in older adults are unclear. Our objective was to compare the functional mobility of people aged 70 to 79 years by thyroid function categorized by thyrotropin (TSH) level as euthyroid (>or=0.4 to <4.5 mIU/L), mild subclinical hypothyroid (>or=4.5 to <7.0 mIU/L), or moderate subclinical hypothyroid (>or=7.0 to <or=20.0 mIU/L with a normal free thyroxine level) cross-sectionally and over 2 years. METHODS: A total of 2290 community-dwelling residents participating in the year 2 clinic visit (July 1998-June 1999) of the Health, Aging, and Body Composition (Health ABC) Study, who had measured TSH level, had the capacity to walk 20 m unaided, and were not taking thyroid medication or had TSH levels consistent with hyperthyroidism or hypothyroidism. Main outcome measures included self-reported and performance-based measures of mobility (usual and rapid gait speed and endurance walking ability) assessed at study baseline (year 2) and 2 years later. RESULTS: In age- and sex-adjusted analyses, the mild subclinical hypothyroid group (vs the euthyroid group) demonstrated better mobility (faster mean usual and rapid gait speed [1.20 vs 1.15 m/s and 1.65 vs 1.56 m/s, respectively; P < .001] and had a higher percentage of those with good cardiorespiratory fitness and reported walking ease [39.2% vs 28.0% and 44.7% vs 36.5%, respectively; P < .001]). After 2 years, persons with mild subclinical hypothyroidism experienced a similar decline as the euthyroid group but maintained their mobility advantage. Persons with moderate subclinical hypothyroidism had similar mobility and mobility decline as the euthyroid group. CONCLUSION: Generally, well-functioning 70- to 79-year-old individuals with subclinical hypothyroidism do not demonstrate increased risk of mobility problems, and those with mild elevations in TSH level show a slight functional advantage.
Authors: John P Walsh; Alexandra P Bremner; Max K Bulsara; Peter O'leary; Peter J Leedman; Peter Feddema; Valdo Michelangeli Journal: Clin Endocrinol (Oxf) Date: 2005-12 Impact factor: 3.478
Authors: Annewieke W van den Beld; Theo J Visser; Richard A Feelders; Diederick E Grobbee; Steven W J Lamberts Journal: J Clin Endocrinol Metab Date: 2005-09-20 Impact factor: 5.958
Authors: Anne R Cappola; Linda P Fried; Alice M Arnold; Mark D Danese; Lewis H Kuller; Gregory L Burke; Russell P Tracy; Paul W Ladenson Journal: JAMA Date: 2006-03-01 Impact factor: 56.272
Authors: Anne B Newman; Eleanor M Simonsick; Barbara L Naydeck; Robert M Boudreau; Stephen B Kritchevsky; Michael C Nevitt; Marco Pahor; Suzanne Satterfield; Jennifer S Brach; Stephanie A Studenski; Tamara B Harris Journal: JAMA Date: 2006-05-03 Impact factor: 56.272
Authors: Nicolas Rodondi; Anne B Newman; Eric Vittinghoff; Nathalie de Rekeneire; Suzanne Satterfield; Tamara B Harris; Douglas C Bauer Journal: Arch Intern Med Date: 2005-11-28
Authors: Jacobijn Gussekloo; Eric van Exel; Anton J M de Craen; Arend E Meinders; Marijke Frölich; Rudi G J Westendorp Journal: JAMA Date: 2004-12-01 Impact factor: 56.272
Authors: Jacqueline Jonklaas; Antonio C Bianco; Andrew J Bauer; Kenneth D Burman; Anne R Cappola; Francesco S Celi; David S Cooper; Brian W Kim; Robin P Peeters; M Sara Rosenthal; Anna M Sawka Journal: Thyroid Date: 2014-12 Impact factor: 6.568
Authors: T Juárez-Cedillo; L Basurto-Acevedo; S Vega-García; A Sánchez-Rodríguez Martha; R Retana-Ugalde; E Juárez-Cedillo; C Gonzalez-Melendez Roberto; J Escobedo-de-la-Peña Journal: J Endocrinol Invest Date: 2017-03-25 Impact factor: 4.256
Authors: Qu Tian; Luigi Ferrucci; Susan M Resnick; Eleanor M Simonsick; Michelle D Shardell; Bennett A Landman; Vijay K Venkatraman; Christopher E Gonzalez; Stephanie A Studenski Journal: Brain Imaging Behav Date: 2016-09 Impact factor: 3.978